OncoSec Medical (LTS:0KC7) EBITDA Margin %: 0.00% (As of Jan. 2023)


LTS:0KC7 OncoSec Medical Inc LTS:0KC7
40 GF Score
Price $143.00
View Full Analysis

What is OncoSec Medical EBITDA Margin %?

OncoSec Medical LTS:0KC7 40 EBITDA Margin % is 0.00% as of Jan. 2023. GuruFocus rates LTS:0KC7 with a GF Score™ of 40/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. OncoSec Medical's EBITDA for the three months ended in Jan. 2023 was $-6.81 Mil. OncoSec Medical's Revenue for the three months ended in Jan. 2023 was $0.00 Mil. Therefore, OncoSec Medical's EBITDA margin for the quarter that ended in Jan. 2023 was 0.00%.

OncoSec Medical  (LTS:0KC7) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

OncoSec Medical EBITDA Margin % Related Terms

OncoSec Medical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical EBITDA Margin % Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0KC7 vs NOVNQ, USRM, VRTX: EBITDA Margin % Comparison

For the Biotechnology subindustry, OncoSec Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSec Medical EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's EBITDA Margin % falls into.


LTS:0KC7
40GF Score
OncoSec Medical Inc LTS:0KC7
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSec Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

OncoSec Medical's EBITDA Margin % for the fiscal year that ended in Jul. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Jul. 2022 )/Revenue (A: Jul. 2022 )
=-36.427/0
= %

OncoSec Medical's EBITDA Margin % for the quarter that ended in Jan. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2023 )/Revenue (Q: Jan. 2023 )
=-6.814/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
OncoSec Medical (LTS:0KC7) has a EBITDA Margin % of 0.00% as of Jan. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OncoSec Medical and its competitors.
Is OncoSec Medical's EBITDA Margin % too high?
OncoSec Medical's current EBITDA Margin % is 0.00%. Overall, OncoSec Medical has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does OncoSec Medical's EBITDA Margin % compare to NOVNQ and USRM?
OncoSec Medical's EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on OncoSec Medical and its competitors. OncoSec Medical's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (LTS:0KC7) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. OncoSec Medical's overall GF Score™ is 40/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For OncoSec Medical (LTS:0KC7), the current EBITDA Margin % is 0.00% as of Jan. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
40GF Score

Get the complete analysis for LTS:0KC7

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$143.00
Price